Phase II/III Autism Clinical Trial Shows Significant...

Phase II/III Autism Clinical Trial Shows Significant Improvements in Anxiety and Depression at 8 Weeks

Highlights:

• Important secondary endpoint from Phase II/III autism spectrum disorder (ASD) clinical trial at 8 weeks was the child’s change in Anxiety, Depression and Mood Scale (ADAMS)

• Statistically significant and clinically meaningful treatment effect in ADAMS total score shown, with children showing significant improvement from day 0 to week 8 (p<0.001)

• Approximately 40-50% of children with autism experience clinically significant levels of anxiety.1 The prevalence of depression in autistic children has been estimated at 10-20%.2

• Children receiving NTI164 showed significant clinical improvements on top of existing anxiety/depression medications (62% of NTI164 pts were on such treatments at enrolment)